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Brief Report

Brief Report: A Phase II “Window-of-Opportunity”
Frontline Study of the mTOR Inhibitor, Temsirolimus
Given as a Single Agent in Patients with Advanced NSCLC,
an NCCTG Study
Thanyanan Reungwetwattana, MD,*† Julian R. Molina, PhD, MD,* Sumithra J. Mandrekar, PhD,*
Katie Allen-Ziegler,* Kendrith M. Rowland, MD,‡ Nicholas F. Reuter, MD,§ Ronnie F. Luyun, MD,‡
Grace K. Dy, MD,|| Randolph S. Marks, MD,* Steven E. Schild, MD,¶ James R. Jett, MD,# and
Alex A. Adjei, PhD, MD||

Background: In an effort to evaluate the single agent activity of
temsirolimus in previously untreated non–small-cell lung cancer, the
North Central Cancer Treatment Group undertook a frontline “window-of-opportunity” study.
Methods: Patients received 25 mg of temsirolimus administered
intravenously as a weekly 30 minute infusion, on a 4-week cycle.
Based on a two-stage Fleming design, the treatment would be promising if at least four of the first 25 evaluable patients in stage I or
at least six of the 50 evaluable patients at the end of stage II have a
confirmed response. Fresh tumor biopsies were obtained to evaluate
predictive markers of temsirolimus activity.
Results: A total of 55 patients were enrolled with 52 patients being
evaluable. The median age was 64 years. Adverse events (grade 3/4)
occurring in 33 patients included dyspnea (12%), fatigue (10%),
hyperglycemia (8%), hypoxia (8%), nausea (8%), and rash/desquamation (6%). The clinical benefit rate was 35% with four patients
achieving a confirmed partial response and 14 patients with stable
disease for 8 weeks or more. The 24-week progression-free survival
rate was 25%. Median progression-free survival and overall survival
were 2.3 and 6.6 months, respectively. Expression of p70s6 kinase,
phospho-p70s6 kinase, Akt, phospho-Akt, and phosphatase and
tensin homolog mutation did not correlate with clinical outcome.
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Conclusions: Temsirolimus given as a single agent in frontline therapy
in patients with non–small-cell lung cancer was tolerable and demonstrated clinical benefit but did not meet the primary objective in this
study. Patient selection will be needed to enhance the efficacy.
Key Words: mTOR inhibitors, Advanced non–small-cell lung carcinoma, Temsirolimus, Window of opportunity.
(J Thorac Oncol. 2012;7: 919–922)

T

he prognosis of advanced non–small-cell lung cancer
(NSCLC) patients treated with platinum-doublet regimens
remains poor with a median progression-free survival (PFS)
of 3.1 to 5.5 months and a median overall survival (OS) of
7. to -11.3 months.1 Advances in maintenance chemotherapy
still yield a median OS of 12 to 15 months with pemetrexed
or erlotinib.2,3 Thus, novel therapies are required to improve
treatment outcomes.
The phosphoinositide 3–kinase/Akt/mammalian target
of rapamycin (mTOR) pathway is one of the key signaling pathways in cancer. It plays roles in cell growth, cell proliferation,
angiogenesis, and protein synthesis. It is also dysregulated in
many human cancers including NSCLC.4 Phosphorylation of
mTOR, in response to the activation of a growth receptor by its
ligand, leads to the modulation of two different pathways: the
eukaryotic initiation factor 4E binding protein-1 and the 40S
ribosomal protein S6 kinase (p70s6k).5 The tumor suppressor
gene phosphatase and tensin homolog (PTEN), is a negative
regulator of the pathway. Loss or inactivating mutations of
this gene result in gain of function of the phosphoinositide3-kinase, catalytic, alpha polypeptide gene itself and the constitutively active mutant forms of receptor tyrosine kinases
or the Ras oncogene, which occur frequently in NSCLC.4
The mTOR inhibitors such as temsirolimus, everolimus,
and deforolimus are being evaluated in cancer clinical trials.
Everolimus and temsirolimus have been approved for the therapy of renal cell carcinoma.6,7
It had been assumed that the efficacy of novel agents in
NSCLC will be more accurately determined if these agents
were tested in the frontline setting because of the emergence
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of resistance arising from exposure to various therapies over
time. On the basis of this assumption, a frontline “windowof-opportunity” study was designed. Patients with previously untreated NSCLC received single-agent temsirolimus,
and were closely monitored. Standard platinum-based chemotherapy was introduced at the first sign of progression.
Furthermore, putative predictive markers of temsirolimus
activity (p70S6k, Akt, and PTEN) were evaluated.

METHODS
Chemotherapy naïve patients with histologic or cytologic evidence of measurable metastatic NSCLC were eligible
for this study. Other eligibility criteria were standard for phase
II studies (see Supplementary Content, http://links.lww.com/
JTO/A274).
Temsirolimus at a dose of 25 mg dissolved in 250 ml of
0.9% saline was administered intravenously over 30 minutes
every week (4 week-cycle length) until progression, unacceptable toxicity, patient refusal, or investigator’s decision to
remove patients from the study.
Biomarkers of temsirolimus effect were evaluated in
tumor biopsy samples obtained from 13 patients at baseline. Thirteen usable tumor biopsy samples were obtained.
Immunohistochemistry was performed for p70s6 kinase,
Phospho-p70s6 kinase, Akt, phospho-Akt, and PTEN expression. PTEN mutation was also evaluated by direct sequencing.
Immunohistochemistry was graded as previously described
and the staining index was calculated as staining intensity (0–3
scale) multiplied by percentage of tumor cells stained (see
Supplementary Content, http://links.lww.com/JTO/A274).8
A two-stage single arm Phase II study based on a
Fleming design9 was used to assess the primary endpoint of
confirmed response rate (CRR), which is complete response
and partial response (PR) by Response Evaluation Criteria in
Solid Tumors10 in patients with metastatic NSCLC to temsirolimus on two consecutive evaluations at least more than 4
weeks apart. The treatment would be considered promising if
at least four of the first 25 evaluable patients have a CRR or at
least six of the 50 evaluable patients at the end of study have
a CRR. If only one success out of 25 patients is observed at
the end of stage I, the treatment regimen would be considered
ineffective and the study would be terminated. However, in
the event that only 2 or 3 successes were observed in stage I,
the study would proceed to stage II. This design with a sample
size of 50 evaluable patients had an exact significance level of
0.05 and 94% power to detect an effective treatment given that
the true CRR is at least 20%.
The secondary endpoints included the 24-week PFS
rate, OS, clinical benefit rate (confirmed response and confirmed stable disease [SD; lasting 8 weeks or more from the
time of first SD assessment]), and evaluation of predictive
markers of activity of temsirolimus.

RESULTS
Patient and Treatment Characteristics
A total of 55 patients (52 evaluable) were enrolled
between February 27, 2004 and November 3, 2006. One
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patient died before study initiation and 2 were deemed ineligible. Baseline characteristics for the 52 patients are summarized in Table 1. The median follow-up for the two surviving
patients is 17.9 months (range, 4.1–31.7). The median number
of treatment cycles delivered was 2 (range, 1–18). 39 patients
(75%) discontinued treatment because of disease progression,
six patients (12%) died on study because of their disease, five
patients (10%) refused further treatment, one patient (2%)
changed to alternate-treatment, and one patient (2%) discontinued because of adverse events.
All 52 evaluable patients were assessed for adverse events
according to the common terminology criteria for adverse
events version 3.0. Grade 3+ adverse events were reported in
33 patients (64%). Grade 4+ adverse events were reported in
12 patients (23%). The most common (occurring in three or
more patients) grade 3/4 events were dyspnea (12%), fatigue
(10%), hyperglycemia (8%), hypoxia (8%), nausea (8%), and
rash/desquamation (6%). There were no toxic deaths.
At stage I, two confirmed PRs were observed and thus
per design, the study reopened for stage II accrual. Among
all 52 evaluable patients, the clinical benefit rate was 35%
(18/52). Four patients (8%, 95% confidence interval (CI);
2–19%) achieved a confirmed PR (Fig. 1) and 14 patients
(27%, 95% CI; 16%–41%) had confirmed SD. The 24-week
PFS rate was 25% (13/52: 95% CI: 14%–39%). The median
PFS and OS were 2.3 (95% CI: 1.8–3.7) and 6.6 (95% CI:
3.5–10.4) months, respectively (Fig. 2).
In order to identify possible temsirolimus predictive
markers, we assessed Akt, phosphorylated Akt, p70s6 kinase,
phosphorylated p70s6 kinase, and PTEN in pretreatment
tumor specimens (Fig. 3). There was no statistically significant

TABLE 1. Baseline Patient Characteristics
Characteristics
Median age (range)
Gender
Female
Male
Race
White
Asian
Native Hawaiian or other Pacific Islander
Performance score
0
1
2
Staging
T4 (pleural effusion)
IV
Hepatic metastases
Yes
No
Status of primary tumor
Recurrence
Newly diagnosed

N (%)
64 (44–85)
20 (38.5)
32 (61.5)
49 (94.2)
2 (3.9)
1 (1.9)
25 (48.1)
23 (44.2)
4 (7.7)
8 (15.4)
44 (84.6)
10 (19.2)
42 (80.8)
4 (7.7)
48 (92.3)
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FIGURE 1. Computed tomography chest
showed partial response during the treatment of
one of the participating patients.

FIGURE 2. Kaplan-Meier survival curve. CI, confidence
interval.

relationship between any of biomarkers and the response of
treatment (Table 2). No PTEN mutations were detected in our
population.

DISCUSSION
The effect of single targeted agent therapy in secondline NSCLC is modest, with response rates around 10%,

median PFS around 3 months and median survival around 7 to
8 months.11,12 It had been hypothesized that prior chemotherapy might confer resistance in the tumors, which precluded
the evaluation of the true activity of novel agents.
To address this question, the window of opportunity
design has been suggested. There are ethical concerns with
this approach of using a new agent with unknown efficacy
upfront, when standard treatment is available. We demonstrated in this study that this approach is feasible and ethical when the study is carefully designed to closely monitor
patients and administer standard therapy at the initial sign of
disease progression, but this approach is not recommended in
the unselected population.
In this study, temsirolimus as a single agent in frontline
NSCLC, achieved a clinical benefit rate of 35% (8% confirmed
PR and 27% with stable disease) in 52 patients. The median
PFS was 2.3 months and the OS was 6.6 months, with acceptable toxicity. Although these results did not meet the protocoldefined criteria for success, they did document clinical activity
of temsirolimus as a single agent in NSCLC. Our previous phase
I study of temsirolimus in solid tumors demonstrated a confirmed
PR in previously treated NSCLC lasting for 12.7 months.13 The
phase II study of everolimus in second-line NSCLC achieved a
median PFS of 2.6 months, a 4.8 % of overall response rate, and
an overall disease control rate of 47.1%.14
In spite of this early hint of activity, subsequent studies
of mTOR inhibitors as single agents (including the present

FIGURE 3. Immunohistochemistry staining of
p70s6kinase phosphorylation in pretreatment
tumor samples.
Copyright © 2012 by the International Association for the Study of Lung Cancer
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TABLE 2. The Correlation of Akt, Phospho-Akt, p70s6k, and
Phospho-p70s6k by Immunohistochemistry Staining Index
and Treatment Response (N = 13)
IHC Staining
Index
Akt ≥ 200
P-Akt ≥ 200
p70s6k ≥ 200
P-p70s6k ≥ 200

Nonresponse to
Treatment (%)

Response to
Treatment (%)

p Value

58
58
77
78

71
35
76
71

0.39
0.15
1.00
0.48

study) have yielded disappointing results. In recent years, preclinical data have demonstrated that treatment of cell lines with
mTOR inhibitors lead to the downregulation of p70s6K and
phospho 4E binding protein-1 but paradoxically can lead to
an upregulation of Akt phosphorylation.5 This is likely caused
by an inhibition of a normally occurring negative-feedback
loop. An increase in Akt phosphorylation is likely to promote
tumor survival and clearly limits the potential clinical efficacy
of single-agent mTOR inhibitors.
Predictive biomarkers are needed in order to successfully incorporate the mTOR inhibitors into lung cancer therapy.
Forgacs et al. found PTEN/MMAC1 gene mutations in three
of 18 NSCLC cell lines.15 A study done by the neuro-oncology
group of North Central Cancer Treatment Group in recurrent
glioblastoma multiforme patients found significant correlation (p = 0.04) between radiographic improvement after the
treatment with temsirolimus and high levels of p70s6 kinase
phosphorylation in baseline tumor tissue.8 We could not find
any associations of p70s6 kinase, phospho-p70s6 kinase, AKT,
phospho-AKT expression, and the mutation of PTEN with the
clinical outcome in this study. However, the small sample size
precluded any conclusions been drawn (only 4 patients with
PR were included in the response to treatment group). These
biomarkers need to be evaluated in future studies.
In conclusion, this study failed to meet its efficacy endpoint, the window of opportunity design was feasible and
helpful in documenting the clinical activity of temsirolimus in
NSCLC. NSCLC development is a multistep process linked to
several intracellular pathways and several genetic alterations.
Thus, the use of single targeted agent in unselected population
may not be the optimal strategy.
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